BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag 2017;13:733-8. [PMID: 28790832 DOI: 10.2147/TCRM.S133983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Elmowafy AY, El Maghrabi HM, Eldahshan KF, Refaie AF, Elbasiony MA, Matter YE, Saleh HH, Shiha GE, Rostaing L, Bakr MA. Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. Int Urol Nephrol 2019;51:1639-47. [PMID: 31363959 DOI: 10.1007/s11255-019-02246-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ghanaat K, Sharafi H, Alavian SM. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urol Mon 2021;13. [DOI: 10.5812/numonthly.114049] [Reference Citation Analysis]
3 Taneja S, Duseja A, De A, Mehta M, Ramachandran R, Kumar V, Kohli HS, Gupta KL, Dhiman RK, Chawla Y. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Dig Dis Sci 2018;63:1334-40. [PMID: 29484572 DOI: 10.1007/s10620-018-4979-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
4 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 2021;41:578-89. [DOI: 10.1016/j.nefroe.2021.11.011] [Reference Citation Analysis]
5 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Reference Citation Analysis]
6 Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00126-8] [Reference Citation Analysis]
7 Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J 2021;18:69. [PMID: 34193156 DOI: 10.1186/s12954-021-00519-y] [Reference Citation Analysis]
8 Han Q, Fan X, Wang X, Wang Y, Deng H, Zhang X, Zhang K, Li N, Liu Z. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J 2019;16:74. [PMID: 31159813 DOI: 10.1186/s12985-019-1184-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Shehadeh F, Kalligeros M, Byrd K, Shemin D, Mylonakis E, Martin P, D'Agata EMC. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Sci Rep 2020;10:14332. [PMID: 32868869 DOI: 10.1038/s41598-020-71205-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Skladany L, Janceková D, Svac J. Hepatitis C virus antibodies in outpatients with chronic kidney disease. Clin Exp Hepatol 2018;4:267-70. [PMID: 30603675 DOI: 10.5114/ceh.2018.80129] [Reference Citation Analysis]
11 Majd Jabbari S, Maajani K, Merat S, Poustchi H, Sepanlou SG. An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLoS One 2021;16:e0246594. [PMID: 33566846 DOI: 10.1371/journal.pone.0246594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]